Tag Archives: Citius Oncology
Citius Pharmaceuticals Follow Up
The launch of LYMPHIR is underway. Citius reported $7.1 million of revenues for the nine months ended June 30. However, its YTD net loss widened to $49.4 million from $31.0 million a year ago, due mostly to $19.7 million of … Continue reading
Posted in CTXR
Tagged Citius Oncology, Citius Pharmaceuticals, CTOR stock research, CTXR stock research
Leave a comment